Edition:
India

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

28.78USD
1:30am IST
Change (% chg)

$1.56 (+5.73%)
Prev Close
$27.22
Open
$27.31
Day's High
$28.86
Day's Low
$27.04
Volume
433,278
Avg. Vol
519,813
52-wk High
$136.45
52-wk Low
$25.62

Latest Key Developments (Source: Significant Developments)

Tesaro Q2 Loss Per Share $3.04
Friday, 3 Aug 2018 

TESARO Inc ::TESARO ANNOUNCES SECOND-QUARTER 2018 OPERATING RESULTS.Q2 LOSS PER SHARE $3.04.Q2 REVENUE $54 MILLION VERSUS I/B/E/S VIEW $63.3 MILLION.Q2 EARNINGS PER SHARE VIEW $-2.65 -- THOMSON REUTERS I/B/E/S.DATA EXPECTED FROM TSR-042 (ANTI-PD-1) GARNET NSCLC AND MSI-HIGH ENDOMETRIAL EXPANSION COHORTS IN 2H 2018.SEES 2018 TOTAL NET, WORLDWIDE REVENUE OF $250 MILLION TO $265 MILLION.REVISING ITS 2018 FINANCIAL GUIDANCE TO REFLECT DIVESTITURE OF VARUBI IN U.S. AND CANADA.FY2018 REVENUE VIEW $302.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer
Tuesday, 27 Mar 2018 

March 26 (Reuters) - Tesaro Inc ::DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER.TESARO INC - ‍EFFICACY OF NIRAPARIB IN COMBINATION WITH AN ANTI-PD-1 MAB SURPASSES HISTORICAL EFFICACY BENCHMARKS FOR PD-1 OR PARP MONOTHERAPIES​.TESARO INC - COMBINATION OF NIRAPARIB WITH PEMBROLIZUMAB WAS WELL TOLERATED WITH AN INCIDENCE OF GRADE 3/4 THROMBOCYTOPENIA OF 9%.TESARO-POTENTIAL APPROACH TO REDUCE INCIDENCE OF GRADE 3 OR 4 THROMBOCYTOPENIA IDENTIFIED BASED ON RETROSPECTIVE ANALYSIS OF DATA FROM PHASE 3 NOVA TRIAL.TESARO - IN ADDITION TO THROMBOCYTOPENIA, OTHER MOST COMMONLY OBSERVED GRADE ≥3 ADVERSE EVENTS N STUDY INCLUDED ANEMIA AND NEUTROPENIA.  Full Article

Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion
Saturday, 13 Jan 2018 

Jan 12 (Reuters) - Tesaro Inc ::TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION.TESARO INC - CHANGES TO LABELING INCLUDE MODIFICATIONS TO CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, AND ADVERSE REACTIONS SECTIONS.TESARO - ANAPHYLAXIS, ANAPHYLACTIC SHOCK HAVE BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING, SOME REQUIRING HOSPITALIZATION.TESARO - OTHER "SERIOUS" HYPERSENSITIVITY REACTIONS HAVE ALSO BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING.TESARO - MOST REACTIONS HAVE OCCURRED DURING OR SOON AFTER INFUSION OF VARUBI INJECTABLE EMULSION AND WITHIN FIRST FEW MINUTES OF ADMINISTRATION.  Full Article

Tesaro secures $500 million non-dilutive term loan financing
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Tesaro Inc :Tesaro secures $500 million non-dilutive term loan financing.Loans will mature in December 2024​.Loan facility provides Tesaro with up to $500 million of borrowing capacity available in two tranches​.Plan to use proceeds to strengthen PARP inhibitor franchise in ovarian cancer, expand development of Zejula in other tumor types​.  Full Article

Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Tesaro Inc :Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer.Tesaro Inc - ‍approval supported by "robust" data from a randomized phase 3 trial​.Tesaro Inc - ‍Tesaro plans to launch Zejula in Germany and UK this December, with launches in additional European countries to follow beginning in 2018​.  Full Article

Tesaro reports Q3 loss per share $0.47
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Tesaro Inc ::Tesaro announces third-quarter 2017 operating results.Q3 loss per share $0.47.Q3 revenue $142.8 million versus I/B/E/S view $132.8 million.Q3 earnings per share view $-0.93 -- Thomson Reuters I/B/E/S.Tesaro Inc - ‍positive CHMP opinion issued for zejula in e.u. & commercial launch anticipated to begin by year-end​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

Tesaro and Zai Lab announce collaboration, development and license agreement
Thursday, 29 Sep 2016 

Tesaro Inc: Tesaro and zai lab announce collaboration, development and license agreement . Tesaro has granted to Zai Lab an exclusive license for development of niraparib specifically for china market . Tesaro retains right to co-market in China and receives option to license up to two novel immuno-oncology programs outside China . Companies will establish a joint steering committee to review and oversee all development and commercialization plans . Tesaro will be eligible to receive milestone payments contingent upon Zai Lab achieving certain specified development and commercial goals . Initiated a rolling submission of a new drug application (NDA) for niraparib to FDA, and intends to complete this submission during Q4 . Should co elect not to participate in commercialization of niraparib in china,co willreceive royalty payments on annual net sales from Zai Lab . Tesaro has option to license two novel, discovery-stage immuno-oncology programs from Zai Lab . Additional financial details were not disclosed .Marketing authorization application (MAA) for niraparib is planned for submission to european medicines agency (EMA) in Q4.  Full Article

Photo

European shares enjoy timid rebound though trade war fears linger

LONDON European shares climbed on Wednesday but the modest rebound failed to erase the previous session's losses as investors' fears about an ongoing trade dispute between the United States and China lingered.